Cover is for reference only

Unhealthy pharmaceutical regulation : innovation, politics and promissory science /

"European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmace...

Full description

Saved in:
Bibliographic Details
Main Authors: Abraham, John, 1961- (Author)
Group Author: Davis, Courtney, 1965-
Published: Palgrave Macmillan,
Publisher Address: Houndmills, Basingstoke, Hampshire ; New York, NY :
Publication Dates: 2013.
Literature type: Book
Language: English
Series: Health, technology and society
Subjects:
Pharmaceutical policy > United States.
Pharmaceutical policy > European Union countries.
Drugs > Law and legislation > United States.
Drugs > Law and legislation > European Union countries.
Pharmaceutical industry > Political aspects.
SOCIAL SCIENCE / Sociology / General.
SOCIAL SCIENCE / Disease & Health Issues
POLITICAL SCIENCE / Public Policy / General.
MEDICAL / Health Policy
MEDICAL / Pharmacy
Drug Industry > European Union.
Drug Industry > United States.
Government Regulation > European Union.
Government Regulation > United States.
Legislation, Drug > European Union.
Legislation, Drug > United States.
Summary: "European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "--
Carrier Form: xii, 321 pages : illustrations ; 23 cm.
Bibliography: Includes bibliographical references and index.
ISBN: 9780230008663 (hardback) :
0230008666 (hardback)
Index Number: RA401
CLC: D971.221.6
Call Number: D971.221.6/D261
Contents: Machine generated contents note: -- Introduction * Innovation, Therapeutic Progress and Regulation * The Regulatory Culture of Accelerated Drug Development and Review * Regulatory and Scientific Standards * Reshaping the Evidence-Base * Risk Management Versus Market Withdrawal * Rapid Regulatory Review, Pharmaceutical Innovation and Public Health * Transparency, Public Accountability and Meeting Patients' Needs * Conclusion * References/Bibliography * Index.

Related Book Recommendations